Carol Lange, PhD

Professor of Medicine, Division of Hematology, Oncology and Transplantation

Carol Lange

Contact Info

lange047@umn.edu

Office Phone 612-626-0621

Lab Phone 612-624-1971

Mailing Address:
Cancer and Cardiovascular Research Building
University of Minnesota
2231 6th Street SE
1st Floor Mailroom CCRB
2812A (Campus Delivery Code)
Minneapolis, MN 55455

Administrative Assistant Name
Marilyn Lingard

Administrative Phone
612-625-1405

Administrative Email
linga012@umn.edu

Administrative Fax Number
612-626-3069

PhD, University of Colorado School of Pharmacy, Boulder, CO (1991)

Summary

Dr. Lange is a Professor in the Departments of Medicine and Pharmacology at the University of Minnesota. She received her Ph.D. from the University of Colorado School of Pharmacy in 1991. She holds memberships in The Endocrine Society (Full Member) and Women in Endocrinology. Dr. Lange serves as teaching faculty in the U of MN Department of Pharmacology Graduate Program, Microbiology, Immunology, and Cancer Biology Graduate Program and MD/PhD Combined Program. She has served on several NIH Study Sections including Biochemical Endocrinology and Metabolic Physiology.

Professional Associations

  • Director, Cancer Biology Training Grant (T32), Masonic Cancer Center, University of Minnesota (2010-present)
  • Director, Cell Signaling Program, Masonic Cancer Center, University of Minnesota
  • Tickle Family Land Grant Endowed Chair (2009-present)
  • Associate Editor, Hormones and Cancer
  • Scientific Editor, Endocrine Related Cancer

Research

Research Summary/Interests

Dr. Lange studies the molecular biology of breast cancer. Her laboratory is focused on the study of cross-talk between peptide growth factors and steroid hormone receptors in human breast cancer cells, with the goal of developing better strategies for the treatment of breast and other hormonally influenced and/or epithelial cell-derived cancers. She has served on several NIH Study Sections including Biochemical Endocrinology and Metabolic Physiology.

Signal Transduction in Breast Cancer
The ovarian steroid hormones, estrogen and progesterone, as well as growth factor receptor tyrosine kinase-initiated signaling pathways are required for normal breast development, and these pathways also interact to influence breast tumorigenesis and breast cancer progression. Ongoing research projects in the laboratory include the study of the role of protein tyrosine kinases and mitogen acitivated protein kinase (MAPK) cascades in human breast cancer cell proliferation and survival, and their contribution to mechanisms of steroid hormone resistance in human breast cancer. In order to study problems in breast cancer cell biology, techniques in signal transduction, endocrinology, protein biochemistry and molecular biology are employed. Understanding the role of signaling cross-talk in cell growth control will provide useful information for the development of better strategies for the treatment of breast and other hormonally influenced and/or epithelial cell-derived cancers.

Publications

  • Lange CA, Yee D. Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer. 2011 Jul 4;18(4):C19-24. Print 2011.
  • Hagan CR, Regan TM, Dressing GE, Lange CA. ck2-Dependent Phosphorylation of Progesterone Receptors (PR) on Ser81 Regulates PR-B Isoform-Specific Target Gene Expression in Breast Cancer Cells. Mol Cell Biol. 2011 Jun;31(12):2439-52.
  • Locatelli A, Lange CA. Met Receptors Induce Sam68-dependent Cell Migration by Activation of Alternate Extracellular Signal-regulated Kinase Family Members. J Biol Chem. 2011 Jun 17;286(24):21062-72.
  • Dressing GE, Goldberg JE, Charles NJ, Schwertfeger KL, Lange CA. Membrane progesterone receptor expression in mammalian tissues: a review of regulation and physiological implications. Steroids. 2011 Jan;76(1-2):11-7.
  • Daniel AR, Gaviglio AL, Czaplicki LM, Hillard CJ, Housa D, Lange CA. The progesterone receptor hinge region regulates the kinetics of transcriptional responses through acetylation, phosphorylation, and nuclear retention. Mol Endocrinol. 2010 Nov;24(11):2126-38.
  • Ostrander JH, Daniel AR, Lange CA. Brk/PTK6 signaling in normal and cancer cell models. Curr Opin Pharmacol. 2010 Dec;10(6):662-9. Epub 2010 Sep 9. Review.
  • Castro NE, Lange CA. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells. Breast Cancer Res. 2010;12(4):R60.
  • Charles NJ, Thomas P, Lange CA. 2010. Expression of membrane progesterone receptors (mPR/PAQR) in ovarian cancer cells: implications for progesterone-induced signaling events. Horm Cancer.;1(4):167-76.
  • Daniel AR, Lange CA. Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells. Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14287-92.
  • Daniel AR, Knutson TP, Lange CA. Signaling inputs to progesterone receptor gene regulation and promoter selectivity. Mol Cell Endocrinol. 2009 Sep 24;308(1-2):47-52.
  • Dressing GE, Hagan CR, Knutson TP, Daniel AR, Lange CA. Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models. Endocr Relat Cancer. 2009 Jun;16(2):351-61.
  • Girard BJ, Daniel AR, Lange CA, Ostrander JH. 2013. PELP1: A review of PELP1 interactions, signaling, and biology. Mol Cell Endocrinol.
  • Regan Anderson TM, Peacock DL, Daniel AR, Hubbard GK, Lofgren KA, Girard BJ, Schörg A, Hoogewijs D, Wenger RH, Seagroves TN, Lange CA. 2013. Breast Tumor Kinase (Brk/PTK6) Is a Mediator of Hypoxia-Associated Breast Cancer Progression. Cancer Res. Sep 15;73(18):5810-20.
  • Hagan CR, Knutson TP, Lange CA. 2013. A Common Docking Domain in Progesterone Receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells. Nucleic Acids Res.
  • Knutson TP, Lange CA. 2013. Dynamic regulation of steroid hormone receptor transcriptional activity by reversible SUMOylation. Vitam Horm.;93:227-61.
  • Diep CH, Charles NJ, Gilks CB, Kalloger SE, Argenta PA, Lange CA. 2013. Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. Cell Cycle. 12(9):1433-49.
  • Knutson TP, Daniel AR, Fan D, Silverstein KA, Covington KR, Fuqua SA, Lange CA. 2012. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res. 14(3):R95.
  • Locatelli A, Lofgren KA, Daniel AR, Castro NE, Lange CA. 2012. Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression. Horm Cancer. 3(1-2):14-25.
  • Hagan CR, Daniel AR, Dressing GE, Lange CA. 2012. Role of phosphorylation in progesterone receptor signaling and specificity.Mol Cell Endocrinol.357(1-2):43-9.
  • Lofgren KA, Ostrander JH, Housa D, Hubbard GK, Locatelli A, Bliss RL, Schwertfeger KL, Lange CA. 2011. Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK. Breast Cancer Res. 13(5):R89.
  • Daniel AR, Hagan CR, Lange CA. 2011. Progesterone receptor action: defining a role in breast cancer. Expert Rev Endocrinol Metab. ;6(3):359-369.
  • Dressing GE and Lange CA. 2009. Integrated Actions of Progesterone Receptors and Cell Cycle Machinery Regulate Breast Cancer Cell Proliferation. Steroids 74(7): 573-576, (invited peer reviewed review).
  • Hagan CR, Faivre EJ, and Lange CA. 2009. Scaffolding Actions of Membrane-Associated Progesterone Receptors. Steroids 74(7): 568-572, (invited peer review)